Matthew Gall - 19 Mar 2026 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Reporting relationship: Chief Financial Officer
Issuer ticker: KLRS
Reported as of: 19 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Mar 2026, 16:05:05 UTC
Prior SEC filing: 03 Nov 2025
Next SEC filing: 24 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Brett Hagen, Attorney-in-Fact

Key filing fact

Matthew Gall filed Form 4 for Kalaris Therapeutics, Inc. (KLRS) on 20 Mar 2026.

Key facts

This page summarizes Matthew Gall's Form 4 filing for Kalaris Therapeutics, Inc. (KLRS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Mar 2026, 16:05.

Change

Previous filing in this sequence was filed on 03 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001816194 Primary reporting owner

Gall Matthew

Relationship: Chief Financial Officer
Address: C/O KALARIS THERAPEUTICS, INC., 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS
Signature: /s/ Brett Hagen, Attorney-in-Fact
Signature date: 20 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KLRS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +95,000
Change %
Price: $0.000000^*
Shares after: 95,000
Date: 19 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 95,000
Exercise price: $6.81
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.